FDA-approved generic pergolide gives equine PPID care a new option

Zygolide, a new generic pergolide tablet for horses with pituitary pars intermedia dysfunction, or PPID, is drawing attention in equine practice as a lower-cost FDA-approved alternative to Prascend. The U.S. Food and Drug Administration announced approval of Zygolide on January 9, 2026, identifying it as the first generic pergolide tablet for horses and confirming it is bioequivalent to Prascend, the reference product first approved in 2011. Dechra says the product is peppermint flavored and 360-degree scored to support dosing flexibility, themes echoed in recent promotional materials carried by The Horse. (fda.gov)

Why it matters: For equine veterinarians, the practical significance is less about a new mechanism and more about access, adherence, and cost in a chronic disease that often requires lifelong therapy. FDA records show Zygolide is indicated for control of clinical signs associated with PPID, with a labeled starting dose of 2 mcg/kg once daily and dose adjustment up to 4 mcg/kg daily. Dechra is positioning the product around easier administration and affordability, which could matter for pet parents managing senior horses on long-term treatment, especially at higher doses. At the same time, the label keeps familiar pergolide handling cautions in place: tablets should not be crushed, and staff should minimize exposure when splitting them because pergolide can cause irritation and other adverse effects in people. (animaldrugsatfda.fda.gov)

What to watch: Watch for how quickly Zygolide gains formulary and pharmacy traction, and whether price competition changes long-term PPID adherence and monitoring patterns in equine practice. (equinefacilitydesign.com)